UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials

Annals of oncology, 2024-09

2024

Volltextzugriff (PDF)

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

Oncotarget, 2018-10, Vol.9 (81), p.35226-35240

2018

Volltextzugriff (PDF)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors

Frontiers in oncology, 2018-12, Vol.8, p.608-608

2018

Volltextzugriff (PDF)

Central nervous system-specific efficacy of CDK4/6 inhibitors in randomized controlled trials for metastatic breast cancer

Oncotarget, 2019-10, Vol.10 (59), p.6317-6322

2019

Volltextzugriff (PDF)

Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors

Clinical breast cancer, 2024-08

2024

Volltextzugriff (PDF)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

Frontiers in oncology, 2019-07, Vol.9, p.666-666

2019

Volltextzugriff (PDF)

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity

Cell chemical biology, 2019-08, Vol.26 (8), p.1067-1080.e8

2019

Volltextzugriff (PDF)

A Rare Cause of Duodenal Ulcer

Gastroenterology (New York, N.Y. 1943), 2024-04, Vol.166 (4), p.568-571

2024

Volltextzugriff (PDF)

Evaluating the simultaneous electrochemical determination of antineoplastic drugs using LaNiO3/g-C3N4@RGH nanocomposite material

Talanta (Oxford), 2024-10, Vol.278, p.126486, Article 126486

2024

Volltextzugriff (PDF)

Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs

Pharmacological research, 2019-01, Vol.139, p.471-488

Roskoski, Robert

2019

Volltextzugriff (PDF)

The reversible inhibitor SR-4835 binds Cdk12/cyclin K in a noncanonical G-loop conformation

The Journal of biological chemistry, 2024-01, Vol.300 (1), p.105501-105501, Article 105501

2024

Volltextzugriff (PDF)

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

Cell reports (Cambridge), 2019-03, Vol.26 (10), p.2667-2680.e7

2019

Volltextzugriff (PDF)

Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review

Critical reviews in oncology/hematology, 2020-09, Vol.153, p.103029-103029, Article 103029

2020

Volltextzugriff (PDF)

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Annals of oncology, 2021-08, Vol.32 (8), p.1015-1024

2021

Volltextzugriff (PDF)

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of oncology, 2018-07, Vol.29 (7), p.1541-1547

2018

Volltextzugriff (PDF)

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

Frontiers in oncology, 2021-07, Vol.11, p.693104-693104

2021

Volltextzugriff (PDF)

Properties of FDA-approved small molecule protein kinase inhibitors

Pharmacological research, 2019-06, Vol.144, p.19-50

Roskoski, Robert

2019

Volltextzugriff (PDF)

CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer

Oncotarget, 2018-03, Vol.9 (21), p.15658-15672

2018

Volltextzugriff (PDF)

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

Cancer cell, 2018-07, Vol.34 (1), p.9-20

2018

Volltextzugriff (PDF)

Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer

European journal of cancer (1990), 2024-02, Vol.198, p.113480-113480, Article 113480

2024

Volltextzugriff (PDF)

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

Cancer cell, 2018-12, Vol.34 (6), p.893-905.e8

2018

Volltextzugriff (PDF)

A Validated Stability Indicating LC-MS/MS Bio-analytical Method for Analysis of Non-Small Cell Lung Cancer Drug (Mobocertinib) in Human Plasma

Asian journal of chemistry, 2023-09, Vol.35 (10), p.2439-2444

2023

Volltextzugriff (PDF)

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer

Medicinskij sovet, 2019-06 (10), p.72-80

2019

Volltextzugriff (PDF)

Targeting CDK4/6 in patients with cancer

Cancer treatment reviews, 2016-04, Vol.45, p.129-138

2016

Volltextzugriff (PDF)

CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis

Expert review of anticancer therapy, 2021-03, Vol.21 (3), p.283-298

2021

Volltextzugriff (PDF)

1 – 25 von 419

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(356)
Mit Volltextzugriff
(315)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors

Central nervous system-specific efficacy of CDK4/6 inhibitors in randomized controlled trials for metastatic breast cancer

Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity

A Rare Cause of Duodenal Ulcer

Evaluating the simultaneous electrochemical determination of antineoplastic drugs using LaNiO3/g-C3N4@RGH nanocomposite material

Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs

The reversible inhibitor SR-4835 binds Cdk12/cyclin K in a noncanonical G-loop conformation

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

Properties of FDA-approved small molecule protein kinase inhibitors

CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

A Validated Stability Indicating LC-MS/MS Bio-analytical Method for Analysis of Non-Small Cell Lung Cancer Drug (Mobocertinib) in Human Plasma

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer

Targeting CDK4/6 in patients with cancer

CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis

Suchergebnisse filtern